The current financial score of Dare Bioscience Inc is 5.92. Its financial status is weak, and its operating efficiency is low.
The current valuation score of Dare Bioscience Inc is 9.68. Its current P/E ratio is -0.94, which is -164.76% below the recent high of 0.61 and -1937.88% above the recent low of -19.13.
The current earnings forecast score of Dare Bioscience Inc is 8.00. The average price target is 8.33, with a high of 12.00 and a low of 5.00.
The current price momentum score of Dare Bioscience Inc is 4.79. Currently, the stock price is trading between the resistance level at 0.92 and the support level at 0.73, making it suitable for range-bound swing trading.
The current institutional shareholding score of Dare Bioscience Inc is 3.00. The latest institutional shareholding proportion is 8.57%, representing a quarter-over-quarter increase of 23.58%. The largest institutional shareholder is James Simons, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 100.00% decrease in holdings.
The current risk assessment score of Dare Bioscience Inc is 2.19. The company's beta value is 1.08. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.